Dapoxetine - Yuhan Corporation

Drug Profile

Dapoxetine - Yuhan Corporation

Alternative Names: IMD dapoxetine; YHD 1044

Latest Information Update: 01 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Antidepressants; Benzylamines; Naphthalenes; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Premature ejaculation

Most Recent Events

  • 23 Sep 2015 No recent reports on development identified - Phase-III for Premature ejaculation in South Korea (PO)
  • 31 May 2012 Yuhan Corporation completes a phase I/IIa trial in Premature ejaculation in South Korea (NCT01419470)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top